Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib plus rituximab for indolent mantle cell lymphoma (naïve)
2024-511983-97-00Phase 2Authorised
- Sponsor
- GELTAMO
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib and rituximab in mantle cell lymphoma (MCL), sponsored by GELTAMO. Primary endpoint: Complete remission rate at end of Cycle 6. Planned start Jun 2025; status: authorised.
02
Drugs
pirtobrutinibrituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-511983-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511983-97-00.